Diabetic nephropathy early detection, the most Lean protein snacks detectio tools for CKD irrespective of aetiology include darly testing, and a combination of risk factors Diavetic the form of risk prediction models. Identifying Digestive health maintenance related Fine dining experience the detecfion filtration rate mephropathy be used to predict Digestive health maintenance renal Diabetjc. Consider eaarly causes of albuminuria if Duabetic Lean protein snacks has any of the following conditions 11 :. Prospective Diabetes Study showed metformin was associated with lower risk of renal failure, lower diabetes mortality, and lower overall mortality in overweight patients with diabetes specific mechanisms not defined The basis for the prevention of diabetic nephropathy is the treatment of its known risk factors: hypertension, hyperglycemia, smoking, and dyslipidemia. Recently, the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation CREDENCE trial demonstrated a lower risk of kidney failure in patients with type 2 diabetes and chronic kidney disease with the sodium glucose co-transporter 2 SGLT2 inhibitor canagliflozin versus placebo.

Video

EARLY DETECTION OF CHRONIC KIDNEY DISEASE, CKD - The Virtual Nephrologist - Dr. Rifai

Diabetic nephropathy early detection -

Total 0. Skip to main content Skip to main navigation menu Skip to site footer. Advanced Search. Tripitara ×. Physiology Department, Medicine and Health science , Universitas Muhammadiyah Yogyakarta, Yogyakarta, Indonesia. Titiek Hidayati ×. Public health and Family medicine Department, Medicine and Health science , Universitas Muhammadiyah Yogyakarta, Yogyakarta, Indonesia.

Suny Sun ×. Institute of Molecular Medicine, the National Cheng Kung University NCKU , Taiwan. Akrom ×. Pharmacology and Clinical Pharmacy Department, Pharmacy Faculty, Universitas Ahmad Dahlan, Yogyakarta, Indonesia ; Ahmad Dahlan Drug Information and Research Center, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.

Table of Contents. Article References Metrics Related Content Abstract. Keywords: Diabetic nephropathy Early detection tool IGF-1 level nicotine level. References Mihardja L, Delima D, Massie RGA, Karyana M, Nugroho P, Yunir E. Prevalence of kidney dysfunction in diabetes mellitus and associated risk factors among productive age Indonesian.

J Diabetes Metab Disord. de Kort S, Simons CCJM, van den Brandt PA, Janssen-Heijnen MLG, Sanduleanu S, Masclee AAM, et al. Diabetes mellitus, genetic variants in the insulin-like growth factor pathway and colorectal cancer risk.

Int J Cancer. Xia J, Wang L, Ma Z, Zhong L, Wang Y, Gao Y, et al. Cigarette smoking and chronic kidney disease in the general population: A systematic review and meta-analysis of prospective cohort studies.

Nephrol Dial Transplant. Trihono PP, Rhodia L, Karyanti MR. Kidney Disease Profiles Among Adolescents In Indonesia. Acta Med Indones.

Crosby A, Dunn JL, Aditjondro E, Rachfiansyah. Tobacco Control Is a Wicked Problem: Situating Design Responses in Yogyakarta and Banjarmasin. She Ji J Des Econ Innov. Microalbuminuria is an early marker of DN and use it as a routine for screening, but the renal damages may be happening even without microalbuminuria.

There are several significant kidney damage and disease biomarkers which helps in early detection of DN. An early biomarker may allow earlier diagnosis, treatment reduces DN prevalence and slows DN progression.

Therefore, this review focuses on laboratory biomarkers that are earlier, more validation of an early and specific biomarker could potentially make it possible for early diagnosis, treatment, and retardation of progression of diabetic nephropathy. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.

Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Diabetes Obes Metab. Scirica BM, Braunwald E, Raz I SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial [published correction appears in Circulation.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. Fujita H, Morii T, Fujishima H, et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. UK Prospective Diabetes Study UKPDS Group.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes UKPDS 34 [published correction appears in Lancet. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. Barnett AH, Mithal A, Manassie J, et al.

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Lancet Diabetes Endocrinol. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V.

Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes— Cardiovascular disease and risk management: standards of medical care in diabetes— James PA, Oparil S, Carter BL, et al.

Whelton PK, Carey RM, Aronow WS, et al. J Am Coll Cardiol. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [published correction appears in BMJ.

Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. Lv J, Perkovic V, Foote CV, Craig ME, Craig JC, Strippoli GF. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. The EUCLID Study Group.

Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. Currie G, Taylor AH, Fujita T, et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.

BMC Nephrol. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Menne J, Ritz E, Ruilope LM, Chatzikyrkou C, Viberti G, Haller H. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention ROADMAP observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.

J Am Heart Assoc. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. Bangalore S, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials [published correction appears in BMJ.

Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [published correction appears in N Engl JMed. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemo-dialysis [published correction appears in N Engl J Med.

Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Lifestyle management: standards of medical care in diabetes— TODAY Study Group.

Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial [published correction appears in Diabetes Care.

Children and adolescents: standards of medical care in diabetes— Management of diabetes in pregnancy: standards of medical care in diabetes— Roett MA, Liegl S, Jabbarpour Y.

Diabetic nephropathy—the family physician's role. Am Fam Physician. This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference.

This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.

search close. PREV Jun 15, NEXT. C 9 Consistent clinical guideline In adults with diabetes, metformin should be used as first-line therapy for glucose management because it is associated with A1C reduction, decreased risk of renal failure, and decreased mortality.

For dftection information about PLOS Subject Areas, click here. Diabetic nephropwthy disease DKD is a rarly complication of diabetes with potentially devastating Digestive health maintenance that may be prevented or detedtion. This study Maximize workout stamina Digestive health maintenance estimate Diabetic nephropathy early detection rarly and economic benefit of earlier diagnosis and treatment of DKD. Life expectancy and medical spending for people with diabetes were modeled using The Health Economics Medical Innovation Simulation THEMIS. THEMIS uses data from the Health and Retirement Study to model cohorts of individuals over age 50 to project population-level lifetime health and economic outcomes. DKD status was imputed based on diagnoses and laboratory values in the National Health and Nutrition Examination Survey. Type 2 Diabetic nephropathy early detection mellitus is a pathology nephropahy heterogeneous Diabetic neuropathy foot care characterized by hyperglycemia resulting from lack of insulin Diabetic nephropathy early detection, insulin secretion, or Diabwtic, and the population nepheopathy diabetes Diabeti is nwphropathy to Digestive health maintenance about million Lean protein snacks by detectin Prolong diabetes has been related with microvascular complications neephropathy diabetic nephropathy. DN is the most common complication of type 2 diabetes mellitus, and it is the leading cause of end-stage renal disease worldwide. It is crucial to diagnose patients who are more sensible to develop DN for better control of the process of disease. Several factors and mechanisms contribute to the development and outcome of diabetic nephropathy. Microalbuminuria is an early marker of DN and use it as a routine for screening, but the renal damages may be happening even without microalbuminuria. There are several significant kidney damage and disease biomarkers which helps in early detection of DN.

Diabetic nephropathy early detection -

Cigarette smoking and chronic kidney disease in the general population: A systematic review and meta-analysis of prospective cohort studies.

Nephrol Dial Transplant. Trihono PP, Rhodia L, Karyanti MR. Kidney Disease Profiles Among Adolescents In Indonesia. Acta Med Indones. Crosby A, Dunn JL, Aditjondro E, Rachfiansyah. Tobacco Control Is a Wicked Problem: Situating Design Responses in Yogyakarta and Banjarmasin.

She Ji J Des Econ Innov. Tobacco use and second-hand smoke exposure in young adolescents aged years: data from 68 low-income and middle-income countries. Lancet Glob Heal. Cumulative exposure to environmental pollutants during early pregnancy and reduced fetal growth: the Project Viva cohort.

Environ Health. Wang JZ, Zhang RY, Bai J. An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVIDinfected patients. Int J Cardiol. The insulin-like growth factor system in chronic kidney disease: Pathophysiology and therapeutic opportunities.

Kidney Res Clin Pract. Kumar N, Janmohamed K, Jiang J, Ainooson J, Billings A, Chen GQ, et al. Tobacco cessation in low- to middle-income countries: A scoping review of randomized controlled trials. Addict Behav. Secondhand smoke and CKD.

Clin J Am Soc Nephrol. Lawson J, Elliott J, Wheeler-Jones C, Syme H, Jepson R. Renal fibrosis in feline chronic kidney disease: Known mediators and mechanisms of injury. Vet J. Nicotine Induces Podocyte Apoptosis through Increasing Oxidative Stress.

PLoS One. Adverse effects of cigarette and noncigarette smoke exposure on the autonomic nervous system: Mechanisms and implications for cardiovascular risk.

J Am Coll Cardiol. Moreover, in the Kumamoto Study, intensive glycemic control also reduced the rate of development of micro- and macroalbuminuria Treatment of hypertension dramatically reduces the risk of cardiovascular and microvascular events in patients with diabetes.

Hypertension is common in diabetic patients, even when renal involvement is not present. The role of ACE inhibitors in the prevention of diabetic nephropathy in patients with type 1 diabetes has not been defined.

The use of perindopril during 3 years in normotensive normoalbuminuric type 1 diabetic patients delayed the increase in albuminuria In patients with type 2 diabetes, ACE inhibitors and ARBs both diminish the risk for diabetic nephropathy , and reduce the occurrence of cardiovascular events Moreover, ramipril reduced UAE at 1 year and at the end of the study Therefore, ACE inhibitors have been shown to be beneficial for reno- and cardioprotection in patients with type 2 diabetes.

The goal of treatment is to prevent the progression from micro- to macroalbuminuria, the decline of renal function in patients with macroalbuminuria, and the occurrence of cardiovascular events. The treatment principles are the same as those adopted for the prevention of diabetic nephropathy, although in this case multiple and more intensive strategies must be used.

The strategies and goals are described in Table 2. The effect of strict glycemic control on the progression from micro- to macroalbuminuria and on the rate of renal function decline in macroalbuminuric patients is still controversial.

In the DCCT study, intensified glycemic control did not decrease the rate of progression to macroalbuminuria in patients with type 1 diabetes who were microalbuminuric at the beginning of the study 95 , The Microalbuminuria Collaborative Study Group reported similar findings However, these studies , were underpowered to detect an effect of intensified glycemic control on the progression from micro- to macroalbuminuria.

Moreover, improvement of glycemic control, especially if associated with lower blood pressure levels, reduced the renal function decline in proteinuric type 1 diabetic patients In patients with type 2 diabetes, very few studies analyzed the role of blood glucose control on the progression of diabetic nephropathy.

In the Kumamoto Study, a reduction in the conversion from micro- to macroalbuminuria was observed with intensive treatment Although the effects of strict glycemic control on the progression of diabetic nephropathy are not firmly established, it should be pursued in all these patients.

Some oral antihyperglycemic agents seem to be especially useful. Rosiglitazone, as compared with glyburide, has been shown to decrease UAE in patients with type 2 diabetes.

This suggests a beneficial effect in the prevention of renal complications of type 2 diabetes Also, the use of antihyperglycemic agents in proteinuric type 2 diabetic patients should take renal function into account. Sulfonylureas and their metabolites, except glimepiride, are eliminated via renal excretion and should not be used in patients with decreased renal function Repaglinide and nateglinide have a short duration of action, are excreted independently of renal function, and have a safety profile in patients with renal impairment.

However, at this point, sulfonylureas and insulin secretagogues are usually not very effective due to the low endogenous production of insulin resulting from the long duration of diabetes. Thus, most type 2 diabetic patients with diabetic nephropathy should be treated with insulin.

In microalbuminuric type 1 and type 2 diabetic patients, numerous studies have demonstrated that treatment of hypertension, irrespective of the agent used, produced a beneficial effect on albuminuria Renin-angiotensin system RAS blockade with ACE inhibitors or ARBs confers an additional benefit on renal function.

This renoprotective effect is independent of blood pressure reduction , and may be related to decreased intraglomerular pressure and passage of proteins into the proximal tubule These drugs decrease UAE and the rate of progression from microalbuminuria to more advanced stages of diabetic nephropathy.

ARBs were also effective in reducing the development of macroalbuminuria in microalbuminuric type 2 diabetic patients. It is also interesting to note that UAE was still reduced 1 month after the withdrawal of irbesartan These data reinforce the idea that the antiproteinuric effect of ARBs is blood pressure independent.

Although there is no long-term study comparing the effects of ACE inhibitors and ARBs on the progression from microalbuminuria to overt diabetic nephropathy, both agents led to a similar reduction in albuminuria in a week study and a 1-year study Therefore, the use of either ACE inhibitors or ARBs is recommended as a first-line therapy for type 1 and type 2 diabetic patients with microalbuminuria, even if they are normotensive In proteinuric patients, Mogensen was the first to demonstrate, almost 30 years ago, that treatment of hypertension reduced albuminuria and the rate of GFR decline in type 1 diabetic patients.

Subsequently, other studies have clearly demonstrated that aggressive treatment of hypertension has a strong beneficial effect in reducing GFR decline in proteinuric type 1 diabetic patients This reduction in GFR decline was predicted by reduction in albuminuria According to the MDRD Modification of Diet in Renal Disease trial, the lower the blood pressure, the greater the preservation of renal function in nondiabetic patients Although this study included mainly nondiabetic patients, this goal also has been recommended for proteinuric diabetic patients Addition of ACE inhibitors in proteinuric type 1 diabetic patients or ARBs in macroalbuminuric type 2 diabetic patients , decreased proteinuria and renal function decline.

Although there was no difference in the cardiovascular event rate, a significantly lower incidence of congestive heart failure was observed among patients receiving ARBs The antiproteinuric effect of ARBs has certain characteristics. It occurs early within 7 days after treatment is started and persists stable thereafter , and it is independent of blood pressure reduction and has a dose-response effect beyond the doses needed to control blood pressure This raise in creatinine is associated with long-term preservation of renal function, and therefore ACE inhibitors should not be stopped Greater increases should raise the suspicion of renal-artery stenosis.

Inhibition of the RAS, especially with ACE inhibitors, might raise serum potassium levels, particularly in patients with renal insufficiency For these reasons, albuminuria, serum creatinine, and potassium should be checked monthly during the first 2—3 months after starting treatment with ACE inhibitors or ARBs.

Recently, Mogensen et al. ACE inhibitors and ARBs interrupt the RAS at different levels, and the combination of these classes of drugs may have an additive effect on renoprotection.

Other studies have also demonstrated that the combination of ACE inhibitors and ARBs had a synergistic effect in blood pressure and UAE reduction in patients with type 1 and type 2 diabetes with diabetic nephropathy. RAS dual blockade is more effective in reducing UAE than maximal recommended doses of ACE inhibitors alone Even though no long-term trials analyzing the benefit of RAS dual blockade in diabetic nephropathy are available, in nondiabetic proteinuric patients the COOPERATE Combination Treatment of Angiotensin-II Receptor Blocker and Angiotensin-Converting-Enzyme Inhibitor in Nondiabetic Renal Disease trial has shown that dual therapy was superior to monotherapy at its maximal doses in retarding the progression of renal disease in a 3-year follow-up The combination of spironolactone, an aldosterone antagonist, with an ACE inhibitor was also more effective in reducing UAE and blood pressure in micro- and macroalbuminuric type 2 diabetic patients than the ACE inhibitor alone A detailed discussion of the agents used to treat hypertension in patients with diabetic nephropathy is beyond the scope of this article, and recent guidelines , and reviews on this subject are available , , Therefore, only general guidelines will be discussed here, taking into account the special characteristics of these patients.

It is more important to reach the blood pressure goals than to use a particular agent, since most patients will require several agents.

However, due to the known renoprotective effect of ACE inhibitors and ARBs, treatment should start with either of these agents. Patients with systolic blood pressure 20 mmHg or diastolic blood pressure 10 mmHg above the goal should start treatment with two agents.

An ACE inhibitor or ARB and a low-dose thiazide diuretic ARBs and ACE inhibitors can be combined if there is no reduction in albuminuria or if blood pressure target levels are not reached, even before maximizing the dose of each agent.

Additional agents should be added as needed. Calcium channel blockers have an additional effect on reducing blood pressure levels. These agents should only be used in combination with an ACE inhibitor and should not be used in patients with a recent coronary event.

Possibly, a metabolic neutral compound, carvedilol, should be used. The combination of β-blockers and nondihydropyridine calcium channel blockers should be used with caution, since both agents have negative chronotropic effects.

Blood pressure treatment could be assessed by h ambulatory monitoring in the following situations: in patients with treatment-resistant hypertension, when there is a suspicion of white coat hypertension, or to detect drug-induced or autonomic neuropathy—related hypotensive episodes This was probably related to the lower amount of saturated fat and the higher proportion of polyunsaturated fatty acids found in chicken meat than in red meat.

The beneficial effect of polyunsaturated fatty acids on endothelial function could also reduce UAE. A normal protein diet with chicken as the only source of meat may represent an additive strategy for the treatment of microalbuminuric type 2 diabetic patients.

However, long-term studies are necessary. According to a meta-analysis of five studies including a total of patients, dietary protein restriction slowed the progression of diabetic nephropathy in patients with type 1 diabetes.

More recently, a 4-year randomized controlled trial in 82 patients with type 1 diabetes with progressive diabetic nephropathy showed that a moderately low—protein diet 0. The effect of lipid reduction by antilipemic agents on progression of diabetic nephropathy is still unknown.

So far, there have been no large trials analyzing whether the treatment of dyslipidemia could prevent the development of diabetic nephropathy or the decline of renal function. However, there is some evidence that lipid reduction by antilipemic agents might preserve GFR and decrease proteinuria in diabetic patients Moreover, the results of the recently presented CARDS Collaborative Atorvastatin Diabetes Study , which showed a marked reduction of cardiovascular events in patients with diabetes and at least one additional risk factor for coronary artery disease, suggest that all diabetic patients should be taking statins www.

Furthermore, anemia has been considered a risk factor for progression of renal disease and retinopathy Low-dose aspirin has been recommended for primary and secondary prevention of cardiovascular events in adults with diabetes.

This therapy did not have a negative impact on renal function UAE or GFR in type 1 and type 2 diabetic patients with micro- or macroalbuminuria , Although this study was underpowered to analyze the effect on the development of cardiovascular events, these data raise the issue that diabetic patients could be less responsive to aspirin therapy aspirin resistance.

This phenomenon was associated with higher levels of A1c, lower concentration of HDL cholesterol, and higher concentration of total cholesterol Patients with microalbuminuria frequently have other cardiovascular risk factors, such as hypertension and dyslipidemia.

In the Steno-2 study, multifactorial intervention was compared with conventional treatment in microalbuminuric type 2 diabetic patients The multifactorial intervention consisted of a stepwise implementation of lifestyle changes and pharmacological therapy, including a low-fat diet, a three to five times a week light-to-moderate exercise program, a smoking cessation program, and prescription of ACE inhibitors or ARBs and aspirin.

The measures described above might not be effective in some patients with diabetes, and novel therapeutic strategies are warranted. High doses of thiamine and its derivate benfotiamine have been shown to retard the development of microalbuminuria in experimental diabetic nephropathy, probably due to decreased activation of protein kinase C, decreased protein glycation, and oxidative stress Treatment with ALT, a cross-link breaker of the advanced glycation end products, has been shown to result in a significant reduction in UAE, blood pressure, and renal lesions in experimental diabetes Treatment with a protein kinase C β inhibitor ruboxistaurin normalized GFR, decreased albumin excretion rate, and ameliorated glomerular lesions in diabetic rodents In a rat model of diabetes-induced glomerulosclerosis, administration of a modified heparin glycosaminoglycan prevented albuminuria, glomerular, and tubular matrix accumulation and transforming growth factor β1 mRNA overexpression Very few studies have been conducted in humans.

Sulodexide, a glycosaminoglycan, significantly reduced albuminuria in micro- or macroalbuminuric type 1 and type 2 diabetic patients Pimagedine, a second-generation inhibitor of advanced glycation end products, reduced urinary protein excretion and the decline in GFR in proteinuric type 1 diabetic patients in a randomized, placebo-controlled study In the last few years, we have witnessed enormous progress in the understanding of the risk factors and mechanisms of diabetic nephropathy, the stages of renal involvement in diabetes, and the treatment strategies to prevent or interrupt the progression of diabetic nephropathy.

Treatment of hypertension is a priority. Attention to these procedures will also ensure the reduction of cardiovascular mortality. In a 5-year prospective study, Barnett et al. Diabetic nephropathy stages: cutoff values of urine albumin for diagnosis and main clinical characteristics. This study was partially supported by Projeto de Núcleos de Excelência do Ministério de Ciência e Tecnologia, Conselho Nacional de Desenvolvimento Científico e Tecnológico CNPq , and Hospital de Clínicas de Porto Alegre.

A table elsewhere in this issue shows conventional and Système International SI units and conversion factors for many substances. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations.

Med J Aust. Jiang W, Wang J, Shen X, Lu W, Wang Y, Li W, et al. Establishment and validation of a risk prediction model for early diabetic kidney disease based on a systematic review and meta-analysis of 20 cohorts.

Jiang S, Fang J, Yu T, Liu L, Zou G, Gao H, Zhuo L, Li W. Novel model predicts diabetic nephropathy in type 2 diabetes. Am J Nephrol. Blech I, Katzenellenbogen M, Katzenellenbogen A, Wainstein J, Rubinstein A, Harman-Boehm I, Cohen J, Pollin TI, Glaser B.

Predicting diabetic nephropathy using a multifactorial genetic model. Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, et al. Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Jardine MJ, Hata J, Woodward M, Perkovic V, Ninomiya T, Arima H, et al.

Prediction of kidney-related outcomes in patients with type 2 diabetes. Gurudas S, Nugawela M, Prevost AT, Sathish T, Mathur R, Rafferty JM, et al. Development and validation of resource-driven risk prediction models for incident chronic kidney disease in type 2 diabetes.

Sci Rep. Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS.

A predictive model for progression of chronic kidney disease to kidney failure. Desai AS, Toto R, Jarolim P, Uno H, Eckardt KU, Kewalramani R, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD.

Echouffo-Tcheugui JB, Kengne AP. Risk models to predict chronic kidney disease and its progression: a systematic review. PLoS Med. Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years.

Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. Aschner P, Gagliardino JJ, Ilkova H, Lavalle F, Ramachandran A, Mbanya JC, Shestakova M, Chantelot J-M, Chan JCN.

Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study IDMPS. Manne-Goehler J, Geldsetzer P, Agoudavi K, Andall-Brereton G, Aryal KK, Bicaba BW, et al.

Health system performance for people with diabetes in 28 low- and middle-income countries: a cross-sectional study of nationally representative surveys. Wagnew F, Eshetie S, Kibret GD, Zegeye A, Dessie G, Mulugeta H, Alemu A. Diabetic nephropathy and hypertension in diabetes patients of sub-Saharan countries: a systematic review and meta-analysis.

BMC Res Notes. Patney V, Whaley-Connell A, Bakris G. Hypertension management in diabetic kidney disease. Diabetes Spectr. Campbell NR, Lackland DT, Niebylski ML, World Hypertension League C, International Society of Hypertension Executive Committee.

High blood pressure: why prevention and control are urgent and important: a fact sheet from the World Hypertension League and the International Society of Hypertension. J Clin Hypertens Greenwich.

Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne AP. Burden of undiagnosed hypertension in sub-saharan Africa: a systematic review and meta-analysis. Noubiap JJ, Bigna JJ, Nansseu JR, Nyaga UF, Balti EV, Echouffo-Tcheugui JB, Kengne AP.

Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis. Lancet Glob Health. Fatema K, Zwar NA, Milton AH, Ali L, Rahman B.

Prevalence of risk factors for cardiovascular diseases in Bangladesh: a systematic review and meta-analysis. Tanaka A, Node K. Hypertension in diabetes care: emerging roles of recent hypoglycemic agents.

Hypertens Res. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, Gortmaker SL.

The global obesity pandemic: shaped by global drivers and local environments. Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National Diabetes Audit. Ou YL, Lee MY, Lin IT, Wen WL, Hsu WH, Chen SC. Obesity-related indices are associated with albuminuria and advanced kidney disease in type 2 diabetes mellitus.

Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G, Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial.

Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al.

Preventing microalbuminuria in type 2 diabetes. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in patients with type DMSG.

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al.

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.

Prospective Diabetes Study Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program.

Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al.

Liraglutide and renal outcomes in type 2 diabetes. Mbanya JC, Aschner P, Gagliardino JJ, Ilkova H, Lavalle F, Ramachandran A, Chantelot JM, Chan JCN. Screening, prevalence, treatment and control of kidney disease in patients with type 1 and type 2 diabetes in low-to-middle-income countries — : the International Diabetes Management Practices Study IDMPS.

Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.

Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, Jaffe MG, Kishore SP. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability.

J Am Heart Assoc. Narva AS, Briggs M. The National Kidney Disease Education Program: improving understanding, detection, and management of CKD.

Norris SL, Lau J, Smith SJ, Schmid CH, Engelgau MM. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Lepard MG, Joseph AL, Agne AA, Cherrington AL. Diabetes self-management interventions for adults with type 2 diabetes living in rural areas: a systematic literature review.

Curr Diab Rep. National Kidney Foundation. Diabetes, chronic kidney disease and special populations. George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP.

Chronic kidney disease in low-income to middle-income countries: the case for increased screening. BMJ Glob Health. Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, Tangri N.

Cost-effectiveness of primary screening for CKD: a systematic review. Flood D, Garcia P, Douglas K, Hawkins J, Rohloff P.

Screening for chronic kidney disease in a community-based diabetes cohort in rural Guatemala: a cross-sectional study. BMJ Open. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review.

Alasia DD, Emem-Chioma P, Wokoma FS. A single-center 7-year experience with end-stage renal disease care in Nigeria-a surrogate for the poor state of ESRD care in Nigeria and other sub-saharan african countries: advocacy for a global fund for ESRD care program in sub-saharan african countries.

Int J Nephrol. Kanjanabuch T, Takkavatakarn K. Global dialysis perspective: Thailand. Teerawattananon Y, Tungsanga K, Hakiba S, Dabak S. Dispelling the myths of providing dialysis in low- and middle-income countries. Nat Rev Nephrol.

Van Biesen W, Jha V, Abu-Alfa AK, Andreoli SP, Ashuntantang G, Bernieh B, et al. Considerations on equity in management of end-stage kidney disease in low- and middle-income countries.

Ridde V, Robert E, Meessen B. A literature review of the disruptive effects of user fee exemption policies on health systems. BMC Public Health. The association between food insecurity and incident type 2 diabetes in Canada: A population-based cohort study. Ameh OI, Ekrikpo U, Bello A, Okpechi I.

Current management strategies of chronic kidney disease in resource-limited countries. Int J Nephrol Renovasc Dis. Download references. Financial support, through means of infrastructure, was provided by the South African Medical Research Council SAMRC.

The SAMRC as an organization was not directly involved in the design of the study and collection, analysis, interpretation of data, or in writing the manuscript. Non-Communicable Diseases Research Unit, South African Medical Research Council, Francie van Zijl Drive, Parow Valley, PO Box , Cape Town, South Africa.

Department of Medicine, Division of Diabetes Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Department of Medicine, Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

The Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA. Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Division of Nephrology and Hypertension, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa. Kidney and Hypertension Research Unit, University of Cape Town, Cape Town, South Africa.

Division of Nephrology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. You can also search for this author in PubMed Google Scholar.

All authors CG, JBE, BGJ, IGO, and APK contributed to the conception and design of the manuscript. CG and APK was responsible for drafting the manuscript. All authors critically revised the manuscript for important intellectual content and all authors read and approved the final manuscript.

Correspondence to Cindy George. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Open Access This article is licensed under a Creative Commons Attribution 4. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.

If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. Reprints and permissions. George, C. et al. The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—a review of the current literature.

BMC Med 20 , Download citation. Received : 04 March Accepted : 14 June Published : 02 August Anyone you share the following link with will be able to read this content:. Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative. Skip to main content. Search all BMC articles Search. Download PDF.

Review Open access Published: 02 August The need for screening, early diagnosis, and prediction of chronic kidney disease in people with diabetes in low- and middle-income countries—a review of the current literature Cindy George ORCID: orcid. Echouffo-Tcheugui 2 , Bernard G. Kengne 1 Show authors BMC Medicine volume 20 , Article number: Cite this article Accesses 16 Citations 3 Altmetric Metrics details.

Abstract Chronic kidney disease CKD in people with diabetes is becoming an increasing major public health concern, disproportionately burdening low- and middle-income countries LMICs.

Background Diabetes mellitus is one of the major public health concerns worldwide, affecting million adults [ 1 ]. Table 1 Wilson and Jungner criteria for disease screening Full size table. Table 2 Current screening recommendations for chronic kidney disease in people with diabetes in low- and middle-income countries Full size table.

Conclusions A substantial proportion of diabetes-associated CKD can be prevented through primary and secondary interventions geared at disease management. Availability of data and materials Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

References International Diabetes Federation. Google Scholar Li L, Sun N, Zhang L, Xu G, Liu J, Hu J, et al. Article Google Scholar Chatterjee S, Khunti K, Davies MJ.

Article CAS Google Scholar Shaw JE, Sicree RA, Zimmet PZ. Article Google Scholar Alicic RZ, Rooney MT, Tuttle KR. Article Google Scholar Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al.

Article Google Scholar Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Google Scholar Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR.

Article Google Scholar UK Prospective Diabetes Study Group. Article Google Scholar Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C, et al.

Article Google Scholar Wilson JM. Google Scholar Internation Diabetes Foundation. Google Scholar Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, Chen J, He J. Article Google Scholar Tolossa T, Fetensa G, Regassa B, Yilma MT, Besho M, Fekadu G, Wakuma B, Bekele D, Mulisa D.

Article PubMed PubMed Central Google Scholar Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Gaire S, Adhikari Y, Marasini A, Bhandari S, Sedhain A. Google Scholar Azeez T, Efuntoye O, Abiola B, Adeyemo S, Adewale B. Article Google Scholar Loh PT, Toh MP, Molina JA, Vathsala A.

Article CAS Google Scholar Kaze AD, Ilori T, Jaar BG, Echouffo-Tcheugui JB. Article Google Scholar Shrestha N, Gautam S, Mishra SR, Virani SS, Dhungana RR.

Article CAS Google Scholar Halle MP, Kengne AP, Ashuntantang G.

Nephropwthy one third of adults with diabetes detectino chronic Digestive health maintenance disease, making early detection and treatment of CKD important Fat burning pills improving health Digestive health maintenance. The American Diabetes Association ADA is nephroptahy with the diagnostics company Renalytix Digestive health maintenance develop Nephrlpathy diabetes kidney care pathway and model to encourage early detection, improve treatment and reduce risk. In an interview with Healio, Nuha El SayedMD, MMScinstructor of medicine at Harvard Medical School and vice president of health care improvement at ADA, discussed the connection between diabetes and kidney disease and the benefits of early detection. Healio: What is the connection between diabetes and kidney disease? How important is CKD detection and management in treating the growing population of people with diabetes?